February 27, 2019

A new publication in the American Journal of Respiratory and Critical Care Medicine, headed by senior author prof. Louis Bont of UMC Utrecht makes a plea to consider further development of the SynGEM vaccine. Commenting on the results of the SynGEM RSV clinical trial, the authors indicate that the fail-fast approach that has been adopted by pharmaceutical industry, makes a challenging endeavor for development of RSV vaccines. Applying the fail-fast approach, the SynGEM vaccine was evaluated based on early results, generated until 56 days after start of the clinical trial. These early results were found inconclusive and consequently funding of Mu...

February 13, 2019

Today phase I clinical trial data of the Mucosis intranasal RSV F protein vaccine were published on-line. The vaccine was shown to be safe and immunogenic and was shown to induce long-lasting anti-RSV antibodies in healthy adults despite high pre-existing antibody levels. The study was designed as a phase I, randomised, double-blind, placebo-controlled trial in 48 healthy volunteers aged 18-49 year and was executed by Imperial College London. Results were published in the high rated journal AJRCCM. 

The vaccine was developed by Mucosis (NL) and incorporates an RSV-F protein with mutations to maint...

Please reload

Virtuvax News

  • LinkedIn Social Icon
  • Twitter Social Icon

© 2016-2017 by Virtuvax BV, The Netherlands